333 related articles for article (PubMed ID: 16315926)
21. Gastrointestinal stromal tumor: 5 years later.
van der Zwan SM; DeMatteo RP
Cancer; 2005 Nov; 104(9):1781-8. PubMed ID: 16136600
[TBL] [Abstract][Full Text] [Related]
22. Correlation of immunophenotype with progression-free survival in patients with gastrointestinal stromal tumors treated with imatinib mesylate.
Chirieac LR; Trent JC; Steinert DM; Choi H; Yang Y; Zhang J; Patel SR; Benjamin RS; Raymond AK
Cancer; 2006 Nov; 107(9):2237-44. PubMed ID: 16998931
[TBL] [Abstract][Full Text] [Related]
23. Imatinib mesylate treatment for advanced gastrointestinal stromal tumor: a pilot study focusing on patients experiencing sole liver metastasis after a prior radical resection.
Zhu J; Wang Y; Hou M; Li HY; Zhang J
Oncology; 2007; 73(5-6):324-7. PubMed ID: 18497504
[TBL] [Abstract][Full Text] [Related]
24. [Gastrointestinal stromal tumours: a broad spectrum of clinical presentations].
Pacelli F; Rosa F; Papa V; Tortorelli AP; Sanchez AM; Covino M; Sofo L; Doglietto GB
Chir Ital; 2007; 59(6):771-9. PubMed ID: 18360981
[TBL] [Abstract][Full Text] [Related]
25. Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era.
Bonvalot S; Eldweny H; Péchoux CL; Vanel D; Terrier P; Cavalcanti A; Robert C; Lassau N; Cesne AL
Ann Surg Oncol; 2006 Dec; 13(12):1596-603. PubMed ID: 16957966
[TBL] [Abstract][Full Text] [Related]
26. Different factors are responsible for predicting relapses after primary tumors resection and for imatinib treatment outcomes in gastrointestinal stromal tumors.
Rutkowski P; Debiec-Rychter M; Nowecki ZI; Wozniak A; Michej W; Limon J; Siedlecki JA; Jerzak Vel Dobosz A; Grzesiakowska U; Nasierowska-Guttmejer A; Sygut J; Nyckowski P; Krawczyk M; Ruka W
Med Sci Monit; 2007 Nov; 13(11):CR515-522. PubMed ID: 17968300
[TBL] [Abstract][Full Text] [Related]
27. [A successfully resected case of liver metastasis of gastrointestinal stromal tumor responding to neoadjuvant chemotherapy with imatinib mesylate and interventional radiology].
Tamura J; Nakayama Y; Kitaguchi K; Ura K; Taira K; Ooe H; Yoshikawa A; Ishigami S; Baba N
Gan To Kagaku Ryoho; 2009 Oct; 36(10):1769-72. PubMed ID: 19838046
[TBL] [Abstract][Full Text] [Related]
28. Role of surgery combined with kinase inhibition in the management of gastrointestinal stromal tumor (GIST).
Hohenberger P; Eisenberg B
Ann Surg Oncol; 2010 Oct; 17(10):2585-600. PubMed ID: 20407930
[TBL] [Abstract][Full Text] [Related]
29. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib.
Andtbacka RH; Ng CS; Scaife CL; Cormier JN; Hunt KK; Pisters PW; Pollock RE; Benjamin RS; Burgess MA; Chen LL; Trent J; Patel SR; Raymond K; Feig BW
Ann Surg Oncol; 2007 Jan; 14(1):14-24. PubMed ID: 17072676
[TBL] [Abstract][Full Text] [Related]
30. Nursing implications of imatinib as molecularly targeted therapy for gastrointestinal stromal tumors.
Griffin JM; Amand MS; Demetri GD
Clin J Oncol Nurs; 2005 Apr; 9(2):161-9. PubMed ID: 15853160
[TBL] [Abstract][Full Text] [Related]
31. Gastric GISTs. Personal experience.
Mingolla GP; Riccio PA; Linguerri R; La Donna M; Zannelli M; Artuso S
Ann Ital Chir; 2007; 78(4):283-8; discussion 288-9. PubMed ID: 17990602
[TBL] [Abstract][Full Text] [Related]
32. [Gastrointestinal stromal tumors: a broad clinical spectrum from incidental -discovery to acute gastrointestinal bleeding].
Siewert E; Tietze L; Maintz C; Geier A; Dietrich CG; Matern S; Gartung C
Z Gastroenterol; 2004 Mar; 42(3):233-42. PubMed ID: 15022111
[TBL] [Abstract][Full Text] [Related]
33. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate.
Wardelmann E; Merkelbach-Bruse S; Pauls K; Thomas N; Schildhaus HU; Heinicke T; Speidel N; Pietsch T; Buettner R; Pink D; Reichardt P; Hohenberger P
Clin Cancer Res; 2006 Mar; 12(6):1743-9. PubMed ID: 16551858
[TBL] [Abstract][Full Text] [Related]
34. Pathology of gastrointestinal stromal tumors.
Hirota S; Isozaki K
Pathol Int; 2006 Jan; 56(1):1-9. PubMed ID: 16398673
[TBL] [Abstract][Full Text] [Related]
35. Use of imatinib mesylate in gastrointestinal stromal tumours: Pan-Birmingham Cancer Network experience.
Wong DW; Lupton SC; Bhatt L; Gross L; Tanière P; Peake DR; Spooner D; Geh JI
Clin Oncol (R Coll Radiol); 2008 Sep; 20(7):517-22. PubMed ID: 18514495
[TBL] [Abstract][Full Text] [Related]
36. Should surgical resection be combined with imatinib therapy for locally advanced or metastatic gastrointestinal stromal tumors?
Yoon SS; Tanabe KK
Ann Surg Oncol; 2007 Jun; 14(6):1784-6. PubMed ID: 17356951
[No Abstract] [Full Text] [Related]
37. Management of gastrointestinal stromal tumors in the imatinib era: selected case studies.
Benjamin RS; Blanke CD; Blay JY; Bonvalot S; Eisenberg B
Oncologist; 2006 Jan; 11(1):9-20. PubMed ID: 16401709
[TBL] [Abstract][Full Text] [Related]
38. Metastatic gastrointestinal stromal tumor with long-term response after treatment with concomitant radiotherapy and imatinib mesylate.
Boruban C; Sencan O; Akmansu M; Atik ET; Ozbek S
Anticancer Drugs; 2007 Sep; 18(8):969-72. PubMed ID: 17667604
[TBL] [Abstract][Full Text] [Related]
39. Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients.
Ménard C; Blay JY; Borg C; Michiels S; Ghiringhelli F; Robert C; Nonn C; Chaput N; Taïeb J; Delahaye NF; Flament C; Emile JF; Le Cesne A; Zitvogel L
Cancer Res; 2009 Apr; 69(8):3563-9. PubMed ID: 19351841
[TBL] [Abstract][Full Text] [Related]
40. The role of neoadjuvant imatinib mesylate therapy in sphincter-preserving procedures for anorectal gastrointestinal stromal tumor.
Wang JP; Wang T; Huang MJ; Wang L; Kang L; Wu XJ
Am J Clin Oncol; 2011 Jun; 34(3):314-6. PubMed ID: 20622646
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
